XML 33 R17.htm IDEA: XBRL DOCUMENT
v2.4.0.6

OPERATING SEGMENT AND GEOGRAPHIC INFORMATION | 6 Months Ended
--- | ---
Jun. 30, 2012
Segment Reporting [Abstract] |
Operating Segment And Geographic Information [Text Block] | OPERATING SEGMENT AND GEOGRAPHIC INFORMATION Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and gross profit. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information. The accounting policies of the segments are the same as the policies discussed in Footnote B – Summary of Significant Accounting Policies. We have three reportable operating segments, Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools. During the third quarter of 2011, we changed the manner in which we report segment results internally. Accordingly, segment results of the prior period have been reclassified to reflect these changes. Beginning with the third quarter of 2011, our chief operating decision-maker reviews our business as having three segments. The change in segments was driven by our corporate strategy to advance personalized medicine through proprietary molecular technologies and world-class clinical and research services. These lines of business are complementary with the Pharmacogenomics Services driving innovation and leading to kit production in our Diagnostic Tools segment and new tests in our Clinical Laboratories. Segment information for the three months ended June 30, 2012 and 2011 is as follows:
| Dollars in Thousands
| 2012
| Clinical Laboratories |  | Pharmacogenomic Services |  | Diagnostic Tools |  | Total
Net Sales | $ | 5,460 |  |  | $ | 348 |  |  | $ | 3,285 |  |  | $ | 9,093 |
Gross Profit | 3,035 |  |  | 82 |  |  | 1,445 |  |  | 4,562 |
Net Income (Loss) before Taxes | (446 | ) |  | (178 | ) |  | 31 |  |  | (593 | )
Income Tax Benefit | — |  |  | — |  |  | (30 | ) |  | (30 | )
Net Income (Loss) | $ | (446 | ) |  | $ | (178 | ) |  | $ | 61 |  |  | $ | (563 | )
Depreciation/Amortization | $ | 431 |  |  | $ | 36 |  |  | $ | 65 |  |  | $ | 532 |
Interest Expense, net | $ | (215 | ) |  | $ | (6 | ) |  | $ | (10 | ) |  | $ | (231 | )
| June 30, 2012
Total Assets | $ | 29,082 |  |  | $ | 2,019 |  |  | $ | 13,571 |  |  | $ | 44,672 |
| Dollars in Thousands
| 2011
| Clinical Laboratories |  | Pharmacogenomic Services |  | Diagnostic Tools |  | Total
Net Sales | $ | 3,864 |  |  | $ | 1,002 |  |  | $ | 2,801 |  |  | $ | 7,667 |
Gross Profit | 2,429 |  |  | 635 |  |  | 1,491 |  |  | 4,555 |
Net Loss before Taxes | (5,456 | ) |  | (287 | ) |  | (359 | ) |  | (6,102 | )
Income Tax Benefit | — |  |  | — |  |  | (104 | ) |  | (104 | )
Net Loss | $ | (5,456 | ) |  | $ | (287 | ) |  | $ | (255 | ) |  | $ | (5,998 | )
Depreciation/Amortization | $ | 407 |  |  | $ | 37 |  |  | $ | 55 |  |  | $ | 499 |
Restructure | $ | — |  |  | $ | — |  |  | $ | 11 |  |  | $ | 11 |
Interest Expense, net | $ | (240 | ) |  | $ | — |  |  | $ | — |  |  | $ | (240 | )
| June 30, 2011
Total Assets | $ | 20,663 |  |  | $ | 1,958 |  |  | $ | 8,079 |  |  | $ | 30,700 |
Segment information for the six months ended June 30, 2012 and 2011 is as follows:
| Dollars in Thousands
| 2012
| Clinical Laboratories |  | Pharmacogenomic Services |  | Diagnostic Tools |  | Total
Net Sales | $ | 8,831 |  |  | $ | 978 |  |  | $ | 6,490 |  |  | $ | 16,299 |
Gross Profit | 4,308 |  |  | 456 |  |  | 2,902 |  |  | 7,666 |
Net Loss before Taxes | (2,614 | ) |  | (97 | ) |  | (574 | ) |  | (3,285 | )
Income Tax Benefit | — |  |  | — |  |  | (26 | ) |  | (26 | )
Net Loss | $ | (2,614 | ) |  | $ | (97 | ) |  | $ | (548 | ) |  | $ | (3,259 | )
Depreciation/Amortization | $ | 847 |  |  | $ | 68 |  |  | $ | 130 |  |  | $ | 1,045 |
Restructure | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Interest Expense, net | $ | (462 | ) |  | $ | (11 | ) |  | $ | (31 | ) |  | $ | (504 | )
| Dollars in Thousands
| 2011
| Clinical Laboratories |  | Pharmacogenomic Services |  | Diagnostic Tools |  | Total
Net Sales | $ | 7,351 |  |  | $ | 1,272 |  |  | $ | 6,525 |  |  | $ | 15,148 |
Gross Profit | 4,328 |  |  | 522 |  |  | 3,892 |  |  | 8,742 |
Net Income (Loss) before Taxes | (8,745 | ) |  | (534 | ) |  | 393 |  |  | (8,886 | )
Income Tax Benefit | — |  |  | — |  |  | (110 | ) |  | (110 | )
Net Income (Loss) | $ | (8,745 | ) |  | $ | (534 | ) |  | $ | 503 |  |  | $ | (8,776 | )
Depreciation/Amortization | $ | 801 |  |  | $ | 71 |  |  | $ | 120 |  |  | $ | 992 |
Restructure | $ | — |  |  | $ | — |  |  | $ | 35 |  |  | $ | 35 |
Interest Expense, net | $ | (473 | ) |  | $ | — |  |  | $ | (5 | ) |  | $ | (478 | )
Net sales for the three and six months ended June 30, 2012 and 2011 by country were as follows:
| Dollars in Thousands |  | Dollars in Thousands
| Three Months Ended |  | Six Months Ended
| June 30, |  | June 30,
| 2012 |  | 2011 |  | 2012 |  | 2011
United States | $ | 6,847 |  |  | $ | 5,669 |  |  | $ | 11,571 |  |  | $ | 10,705 |
Italy | 907 |  |  | 785 |  |  | 1,706 |  |  | 1,611 |
United Kingdom | 232 |  |  | 233 |  |  | 567 |  |  | 491 |
All Other Countries | 1,107 |  |  | 980 |  |  | 2,455 |  |  | 2,341 |
Total | $ | 9,093 |  |  | $ | 7,667 |  |  | $ | 16,299 |  |  | $ | 15,148 |
Other than the United States, Italy and the United Kingdom, no country individually accounted for more than 5% of total net sales. More than 95% of our long-lived assets are located within the United States. Substantially all of the remaining long-lived assets are located within Europe.

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration